Analysis shows cost-effective prevention of RSV in patients with COPD, indicating significant health benefits.
These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.
No takes yet. Share an insight, caveat, or question.
Puggina et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: